Brett R. Beno received his Ph.D. degree in 1997 from the University of California, Los Angeles, under the supervision of Professor K. N. Houk. He remained in Professor Houk’s group as a postdoctoral scholar until joining the Computer Assisted Drug Design department at Bristol-Myers Squibb in 1998. At BMS, he has contributed to many drug discovery programs in the areas of neuroscience and virology and is currently a coleader of a drug discovery team focused on HIV.

Kap-Sun Yeung is a Principal Scientist in the Discovery Chemistry Division at Bristol-Myers Squibb. He has expertise in antiviral drug discovery and key contributions to the HIV-1 attachment inhibitor and HCV NS5B polymerase inhibitor projects at Bristol-Myers Squibb, both of which have progressed compounds into phase II clinical studies. He obtained his Ph.D. in organic synthesis from Cambridge University in the United Kingdom and performed postdoctoral research at the Scripps Research Institute in La Jolla before joining Bristol-Myers Squibb.

Michael D. Bartberger received his undergraduate degree in Chemistry at the University of Central Florida in 1992. After obtaining his Ph.D. in Experimental and Theoretical Physical Organic Chemistry at the University of Florida with Professor W. R. Dolbier, Jr., he moved to the University of California, Los Angeles, as a National Institutes of Health postdoctoral fellow, furthering his studies in theoretical organic chemistry and chemical biology in the research group of Professor K. N. Houk. In 2001, he joined Amgen where he is currently a Principal Scientist in the Computational Chemistry division of Therapeutic Discovery and contributor to research efforts ranging from oncology and metabolic disorders to inflammation and neuroscience.

Lewis D. Pennington is a Principal Scientist in the Medicinal Chemistry group at Amgen in Thousand Oaks, California. Prior to joining Amgen in 2003, he worked at Array BioPharma in Boulder, CO, after receiving a Ph.D. in Chemistry under the mentorship of Professor Larry E. Overman at the University of California, Irvine, in 2002. Preceding his graduate studies, he was employed for three years in the Medicinal Chemistry department at Eli Lilly & Co. in Indianapolis, IN, after earning a B.S. in Chemistry (with Highest Honors in Chemistry) from the University of Michigan, Ann Arbor, in 1993 under the guidance of Professor Masato Koreeda.

Nicholas A. Meanwell received his Ph.D. degree from the University of Sheffield, Sheffield, England, under the supervision of Dr. D. Neville Jones and conducted postdoctoral studies at Wayne State University, Detroit, MI, in collaboration with Professor Carl R. Johnson. He joined Bristol-Myers Squibb in 1982, where he has supervised teams that have advanced clinical candidates in several areas of antiviral drug discovery, including BMY-433771, an inhibitor of respiratory syncytial virus fusion, the HIV-1 attachment inhibitor BMS-626529 that is being developed as the prodrug BMS-663068, the HCV NS3 protease inhibitor asunaprevir, the HCV NS5A inhibitor daclatasvir, and the HCV NS5B RNA-dependent RNA polymerase inhibitor beclabuvir.